|
Yannick Debing1; Abel Acosta Sanchez2; Hannah Vanrusselt1; Dieudonné Kum3; Lars Degrauwe1; Tse-I Lin1; Julian Symons3; Lawrence M. Blatt3; Leonid N. Beigelman3; Andreas Jekle3; 1Aligos Belgium BV, Leuven, Belgium; 2Novalix, Leuven, Belgium; 3Aligos Therapeutics, Inc., South San Francisco, CA, USA
|